GFAP and depressive disorder: In our study, XCHT was proven to alleviate depressive disorders by downregulation of IL‐1β, TNF‐α, and IL‐6 inflammasome, modulating the immune system by inhibiting Iba‐1 and GFAP overexpression, making it a promising candidate for the treatment of depression.